Updated Version! New Look! | #chronicillnessVOICE | SPECIAL EDITION | eyeforpharma Patient Summit Europe ~ My experiences, incl. Im-patient | Carole Scrafton

“what a confusing argument for an onlooker from ‘pharma’ who wanted to know ‘who to trust’ as a patient expert when they’re witnessing different types of ‘patient-expert’ arguing about what constitutes one.”
~ CAROLE, OWN OPINION!… Read More Updated Version! New Look! | #chronicillnessVOICE | SPECIAL EDITION | eyeforpharma Patient Summit Europe ~ My experiences, incl. Im-patient | Carole Scrafton

Advertisements

About Us – #PatientVoice #PatientEmpowerment #PatientAdvocacy #PatientCentricity #PatientLeaders

Due to a number of bad experiences with social media, in the earlier days, I developed a fear of being photographed or filmed.  I am also using these new opportunities in the ‘REAL WORLD’ to help  myself, hopefully, overcome these fears to give me more opportunities for advocacy. … Read More About Us – #PatientVoice #PatientEmpowerment #PatientAdvocacy #PatientCentricity #PatientLeaders

Im-patient UPDATE  >>>  By POPULAR DEMAND We’re now going to North America

If you’re from North America 
and have an idea, or suggestion, that you would like to be put forward for consideration towards the Conference agenda or Conference Design, then we would love to hear from you.  Maybe you’d even like to get more involved!

You can let us know by filling out the survey via the following link  :-)… Read More Im-patient UPDATE  >>>  By POPULAR DEMAND We’re now going to North America

We’re all-a-flutter | Paul Simms Chairman of eyeforpharma  |  21 March 2018

Excerpt:

‘The people who shook our hands and took time out to speak to us made us feel heard; we cannot fault that. Just in shock that such esteemed pharma folks would be interested, and eyeforpharma has taught us that pharma is actually listening. So we can go and spread the word of that now with confidence after experiencing it for ourselves first hand.… Read More We’re all-a-flutter | Paul Simms Chairman of eyeforpharma  |  21 March 2018